A fatal case of empyema thoracis by Nocardia farcinica in an immunocompromised patient.

Empyema thoracis by Nocardia farcinica infection is uncommon. Here we report a rare and fatal infection in a 27-year-old HIV- seropositive male who presented with cough, expectoration, and breathlessness. Nocardia farcinica was isolated from sputum and pus from the pleural cavity. Confirmation of the isolate and minimum inhibitory concentrations (MIC) for various antibiotics was done at the Aerobic Actinomycetes Reference Laboratory, Centres for Disease Control and Prevention (CDC), Atlanta. Patient was treated with suitable antibiotics and antiretroviral drugs in spite of which he eventually succumbed to the disease.

On the transit dose from motorized wedge treatment in Equinox-80 telecobalt unit.

PURPOSE: To estimate the transit dose from motorized wedge (MW) treatment in Equinox-80 telecobalt machine. MATERIALS AND METHODS: Two plans were generated in Eclipse treatment planning system with universal wedge (UW) and MW each for 10 x 10 cm 2 . The transit dose was measured with 0.6 cc cylindrical ion chamber and thermoluminescent dosimeters (TLD) chips at a depth of 5 cm with source to axis distance (SAD) 80 cm. RESULTS: The measured dose with ion chamber was in well agreement with the calculated dose from Eclipse within +/- 2%. The planned dose was 100 cGy while the measured absorbed dose with ion chamber for 15 degrees , 30 degrees , 45 degrees and 60 degrees MW treatment was found to be 100.94, 101.04, 100.72 and 99.33 cGy respectively. For 15 degrees , 30 degrees , 45 degrees and 60 degrees UW treatment, the measured absorbed dose was 99.33, 97.67, 97.77 and 99.57 cGy respectively. Similarly the measured absorbed dose with TLD was within +/- 3% with the planned dose for universal wedge (UW) and MW. From the experimental measurements, it was found that there was no significant contribution of transit dose during MW treatment. CONCLUSION: The actual measurements carried out with ion chamber in Equinox-80 machine for UW and MW revealed no variation between the doses delivered. The doses were comparable for both UW and MW treatments. The results from TLD measurements additionally confirmed no variation between the doses delivered with UW and MW. It was also demonstrated that the observed excess or less transit dose with MW does not have any significant clinical impact. This assured the safe dose delivery with MW.